Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERDAL vs INVEGA SUSTENNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.
Schizophrenia (FDA-approved),Bipolar I disorder (acute manic or mixed episodes) (FDA-approved),Irritability associated with autistic disorder (FDA-approved),Treatment-resistant depression (adjunctive to antidepressants) (off-label),Tourette's disorder (off-label),Obsessive-compulsive disorder (adjunctive) (off-label),Post-traumatic stress disorder (off-label),Delirium (off-label)
Treatment of schizophrenia (FDA-approved),Maintenance treatment of schizoaffective disorder as monotherapy or adjunctive therapy (FDA-approved),Off-label: Bipolar disorder, acute mania, agitation in dementia
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Terminal elimination half-life ranges from 25 to 49 days (mean ~38 days) for deltoid injection and 30 to 50 days (mean ~45 days) for gluteal injection, supporting monthly dosing.
Risperidone is extensively metabolized by cytochrome P450 2D6 (CYP2D6) to its active metabolite, 9-hydroxyrisperidone (paliperidone). A minor pathway involves CYP3A4 and CYP3A5. The metabolite is further metabolized via N-dealkylation and oxidative pathways.
Cr Cl <30 m L/min: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day
Creatinine clearance (Cr Cl) ≥50 m L/min: no adjustment. Cr Cl 30-49 m L/min: 156 mg on day 1, 78 mg on day 8, then 39-78 mg monthly. Cr Cl <30 m L/min: not recommended.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates if exposed during third trimester. Overall, not considered a major teratogen.
Paliperidone, the active metabolite of INVEGA SUSTENNA, is not associated with major malformations in first trimester exposure based on limited data, but infants exposed during the third trimester are at risk for extrapyramidal symptoms and withdrawal after delivery. Risk cannot be excluded.
Risperdal (risperidone) is a second-generation antipsychotic with high affinity for D2 and 5-HT2A receptors. Monitor for orthostatic hypotension during dose titration, especially in elderly. QT prolongation risk is dose-dependent; avoid with hypokalemia, hypomagnesemia, or concomitant QT-prolonging drugs. Therapeutic response for psychosis may take 2-4 weeks. For agitation, consider sublingual or IM formulations. Extrapyramidal symptoms are dose-related; more common at doses >6 mg/day. Prolactin elevation is more pronounced than with other atypical antipsychotics; monitor for galactorrhea, gynecomastia, menstrual irregularities. Weight gain and metabolic syndrome require baseline and periodic monitoring of BMI, fasting glucose, and lipids. Risk of tardive dyskinesia with long-term use. In elderly with dementia-related psychosis, increased mortality.
Administer intramuscularly into the deltoid or gluteal muscle; do not administer intravenously. First dose should be followed by a second dose one week later to achieve therapeutic levels. Do not use if particulate matter or discoloration is present. Priming of the syringe is not required. Rotate injection sites between deltoid and gluteal regions. Monitor for orthostatic hypotension, especially during dose titration. Tardive dyskinesia may occur with long-term use.
No interactions on record
No interactions on record
Common clinical questions about RISPERDAL vs INVEGA SUSTENNA, answered by our medical review team.
RISPERDAL is a Atypical Antipsychotic that works by Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.. INVEGA SUSTENNA is a Atypical Antipsychotic that works by Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERDAL and INVEGA SUSTENNA depend on the specific clinical indication. These are both Atypical Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERDAL is: 2-8 mg orally once daily or divided twice daily; maximum 16 mg/day. The standard adult dose of INVEGA SUSTENNA is: Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERDAL and INVEGA SUSTENNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERDAL is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms an. INVEGA SUSTENNA is classified as Category C. Paliperidone, the active metabolite of INVEGA SUSTENNA, is not associated with major malformations in first trimester exposure based on limited data, but infants exposed during the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Paliperidone is primarily metabolized by the liver via CYP3A4 and CYP2D6 enzymes, with minor contribution from other pathways. It is a substrate of P-glycoprotein. The major metabolites are inactive.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Renal: approximately 59-80% as unchanged drug and metabolites, with about 1% unchanged; biliary/fecal: approximately 20-41% primarily as metabolites.
90% (albumin and alpha-1-acid glycoprotein). Active metabolite 77% bound.
Paliperidone is approximately 74% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
1-2 L/kg. Large Vd indicates extensive tissue distribution and penetration into CNS.
Volume of distribution (Vd) for paliperidone is approximately 487 L (range 395-701 L; equivalent to ~6-10 L/kg for a 70 kg individual), indicating extensive extravascular distribution.
Oral: 70% (with extensive first-pass metabolism). IM: 100% for immediate-release. Long-acting IM: fraction absorbed over depot injection.
IM: Absolute bioavailability of INVEGA SUSTENNA (paliperidone palmitate) is 100% relative to the marketed oral formulation but with controlled release; oral bioavailability of paliperidone is approximately 28%.
Child-Pugh class A or B: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day; Child-Pugh C: not studied
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not studied in severe hepatic impairment (Child-Pugh C).
13-17 yr: 0.5 mg once daily, titrate by 0.5-1 mg/day at ≥24 hr intervals; target 3 mg/day; max 6 mg/day. 10-12 yr: 0.5 mg once daily, titrate by 0.5 mg/day; target 1-2.5 mg/day; max 3 mg/day
Not approved for patients <18 years of age. Safety and efficacy not established.
Initial 0.5 mg twice daily; increase by 0.5 mg increments; max 3 mg/day; monitor for orthostatic hypotension and sedation
No specific dose adjustment for age alone, but renal function should be assessed. Use cautiously due to increased sensitivity and risk of adverse effects. For Cr Cl ≥50 m L/min, follow standard adult dosing.
Increased mortality in elderly patients with dementia-related psychosis. Antipsychotic drugs are not approved for the treatment of dementia-related psychosis.
Grapefruit juice may increase risperidone levels; avoid concurrent use. Risperidone can be taken with or without food. High-fat meals do not affect absorption. Weight gain is common; encourage heart-healthy diet. Alcohol may exacerbate CNS depression and orthostatic hypotension; advise avoidance.
Avoid grapefruit juice as it may increase drug levels. Alcohol can potentiate CNS depression; avoid concurrent use.
Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in breast milk. Milk-to-plasma ratio (M/P) approximately 0.42-0.44. Relative infant dose is about 4-9% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. risk.
Paliperidone is excreted in human breast milk. The milk-to-plasma ratio is unknown. Due to potential for adverse effects in the nursing infant, caution is advised. Consider risk versus benefit and monitor infant for sedation, extrapyramidal symptoms, and weight changes.
Increased plasma volume and hepatic metabolism may lower risperidone concentrations, especially in second and third trimesters. Dose adjustments may be needed; monitor clinical response and consider therapeutic drug monitoring. No standard dose adjustment recommendation; titrate to effect.
Pregnancy may alter paliperidone pharmacokinetics due to increased plasma volume and hepatic metabolism. Dose adjustments should be based on clinical response and tolerability. Consider monitoring serum concentrations to guide dosing. No standard dose adjustment recommended, but may require increased doses.
Take risperidone exactly as prescribed; do not crush or chew tablets.,Avoid alcohol and grapefruit juice as they may worsen side effects.,Rise slowly from sitting or lying to prevent dizziness or fainting.,Report unusual muscle stiffness, tremors, or restlessness immediately.,Notify your doctor if you experience breast swelling, discharge, or sexual dysfunction.,Risperidone may cause drowsiness; avoid driving until you know how the drug affects you.,Do not stop abruptly; withdrawal may cause nausea, vomiting, or insomnia.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.,Avoid overheating or dehydration; increased body temperature may occur.
This medication is given as an injection every month by a healthcare professional.,It is important to keep all appointments for your injections; missing a dose may cause your symptoms to return.,You may experience dizziness or lightheadedness when standing up; rise slowly from sitting or lying positions.,Report any unusual muscle movements, especially of the face or tongue, to your doctor immediately.,Avoid alcohol and grapefruit juice while on this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.